Continuation of trastuzumab beyond disease progression

J Clin Oncol. 2005 Apr 20;23(12):2866-8; discussion 2868-9. doi: 10.1200/JCO.2005.05.177.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Decision Making
  • Disease Progression
  • Drug Administration Schedule
  • Evidence-Based Medicine
  • Female
  • Humans
  • Randomized Controlled Trials as Topic
  • Receptor, ErbB-2
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab